Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research ... review ...

Wondershare UniConverter, a global leader in video conversion, is thrilled to announce the release of UniConverter V16, a ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

You will develop visual communication and design research skills and basic project management and production skills and begin your journey of cultivating systems thinking and practices. Building from ...

The 2024 National Foundation for Cancer Research (NFCR ... The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also ...

highlights the need for further investigation into trastuzumab deruxtecan (Enhertu; T-DXd) in breast cancer treatment. In this interview, she explains some areas for future research of T-DXd based on ...

Through research, RIT is making an impact. RIT is one of the top universities in the nation working at the intersection of technology, the arts, and design with close ties to industry and alumni. RIT ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...

ImmunoPrecise is a biotherapeutic research and technology company that specialises ... the targeted treatment AstraZeneca and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki) . Bath ...

The institute is touted to be the world’s largest community of postgraduate-only art and design students, offering opportunities for cross-disciplinary collaboration. The Rhode Island School ...